2. Anti-infection
  3. SARS-CoV
  4. Ogalvibart

Ogalvibart  (Synonyms: C-135-LS; BMS-986414)

Cat. No.: HY-145644

Molarity Calculator

Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model.

For research use only. We do not sell to patients.

CAS No. : 2599039-60-6

Size Stock
1 mg Get quote
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Ogalvibart Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Human
IC50 & Target

SARS-CoV-2[1].
In Vivo

Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rhesus macaques (3-11 years old)[1].
Dosage: 10 mg/kg (in combination with 10 mg/kg C144LS)
Administration: 75 days before infection
Result: Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
Clinical Trial
CAS No.
SMILES

[Ogalvibart]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ogalvibart Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ogalvibart2599039-60-6C-135-LS BMS-986414BMS986414BMS 986414BMS-986414SARS-CoVSARS coronavirusCOVID19RBDspike (S) glycoproteinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ogalvibart
Cat. No.:
HY-145644
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.